{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"EP Edge Journal Watch","title":"EP Edge® Journal Watch Issue 29: Atrial Fibrillation Ablation vs Antiarrhythmic Drugs, CABANA Progression and Anticoagulation | July 2026","html":"","width":"100%","height":180,"duration":1390,"description":"In EP Edge® Journal Watch Issue 29, July 2026, we examine the evidence reshaping contemporary atrial fibrillation management and the rapidly changing role of catheter ablation.Two major meta-analyses compare catheter ablation with antiarrhythmic drug therapy, addressing rhythm efficacy, serious adverse events, hospitalization, treatment intolerance, and whether medications still deserve an automatic safety advantage. We also review real-world outcomes in older adults after prior antiarrhythmic drug exposure and ask whether another medication or catheter ablation is the more appropriate next step. The episode then explores whether ablation can modify the natural history of AF. A CABANA analysis evaluates progression from paroxysmal to persistent AF, while new registry data challenge the assumption that asymptomatic AF represents a low-risk phenotype. The SUPPRESS-AF analysis examines whether low-voltage area ablation should be guided by the amount of abnormal atrial substrate rather than applied uniformly. We also discuss: Urgent versus elective inpatient AF ablation  Oral anticoagulation after apparently successful AF ablation  The age-dependent relationship between heart failure and ischemic stroke  The SLASH score for predicting AF recurrence after electrical cardioversion Each study is reviewed through its clinical rationale, methodology, statistical interpretation, limitations, and practical implications for electrophysiology practice.Should catheter ablation move earlier in the AF treatment pathway? Should symptom status continue to determine access to rhythm control? When is urgent inpatient ablation justified? Does successful ablation ever eliminate the need for anticoagulation?This episode is designed for cardiac electrophysiologists, cardiologists, fellows, researchers, and clinicians seeking a detailed, clinically relevant review of the latest atrial fibrillation evidence.Read the companion newsletter and subscribe to EP Edge® Journal Watch at...","thumbnail_url":"https://img.transistorcdn.com/C7iPWVsHlGRm13syn3X4eXGLcqOXyzcuH5XmVutqgHc/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9jMzFi/ZTYxOTI1M2U4NGRj/OGZmZjBhMDFlMjFm/NDQwMC5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}